About G1 Therapeutics, Inc.
G1 Therapeutics, Inc. is a commercial-stage biopharmaceutical company focused on the discovery, development and delivery of next generation therapies that improve the lives of those affected by cancer, including the Company’s first commercial product, COSELA™ (Trilaciclib). G1 has a deep clinical pipeline evaluating targeted cancer therapies in a variety of solid tumors, including colorectal, breast, lung, and bladder cancers, and is also advancing rintodestrant, a potential best-in-class oral selective estrogen receptor degrader, or SERD, for the treatment of ER+ breast cancer. In 2020, G1 out-licensed global development and commercialization rights to its differentiated oral CDK4/6 inhibitor, lerociclib.
G1 Therapeutics is based in Research Triangle Park, N.C. For additional information, please visit www.g1therapeutics.com and follow us on Twitter @G1Therapeutics.
View our social community guidelines here: https://www.g1therapeutics.com/social-guidelines
|
|
|
11-50 employees
View all G1 Therapeutics, Inc. employees
|
|
Biotechnology Research
|
|
700 Park Offices Drive, Suite 200, Research Triangle Park, NC 27709, US
|
|
2008
|
|
Biotechnology, Drug Discovery And Development, Cancer / Oncology
|
G1 Therapeutics, Inc. Alternatives
Frequently Asked Questions about G1 Therapeutics, Inc.
The decision makers in G1 Therapeutics, Inc. are Daniel Barnes, Greg Maxfield, Jack Bailey, etc. Click to Find G1 Therapeutics, Inc. decision makers emails.
G1 Therapeutics, Inc. Staff Directory
Search G1 Therapeutics, Inc. Staff Directory
Find accurate personal emails, work emails and phone numbers for employees
Supercharge your
Prospecting &
Outreach with
ContactOut
Supercharge your Prospecting &
Outreach with ContactOut
Find countless prospects outside of LinkedIn fast
Accelerate prospecting with instant access to 350M professionals from 40M companies with the right contact details.
